A growing dispute over the direction of policymaking in Brazil threatens to derail the reform agenda and worsen the country’s public debt problem. Meanwhile, in a rare piece of good news for the region, governments in Mexico and Argentina announced a deal with pharmaceutical firm AstraZeneca to produce a Covid-19 vaccine. However, until there is more clarity over its effectiveness, we will refrain from revising our economic forecasts for the region.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to gain:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services